William Patalon III
I learned a lot of things during the three decades I’ve spent watching, chronicling and digging deep into the machinations of the world’s public companies.
And one of the key lessons I learned was also one of the most powerful when it comes to making money.
The lesson: When troubled companies make serious upgrades in their executive ranks,....More>>>
Payless has suffered from staggering debt and declining sales in a challenging retail landscape. (Photographer: Daniel Acker/Bloomberg)
Payless ShoeSource has become the most recent retailer to file for bankruptcy in the face of hard times.
The discount shoe store sought Chapter 11 bankruptcy protection on Tuesday, saying it needed to shore up its balance sheet in order....More>>>
Tesla (NSDQ:TSLA)announced that it has entered into an agreement to acquire Grohmann Engineering, a German engineering company, which will become Tesla Grohmann Automation and pave the way for the Tesla Advanced Automation Germany headquarters, with other locations to follow. The company plans to add over 1,000 advanced engineering and skilled technician jobs in Germany over the next two years.
Stocks edged higher today despite Donald Trump trashing the health care sector in his press conference today.
The S&P 500 rose 0.3% to 2,275.32 today, while the Dow Jones Industrial Average gained 98.75 points, or 0.5%, to 19,954.28. The Nasdaq Composite advanced 0.2% to5,563.65–and hit its fifth consecutive high–despite the fact that biotech stocks tumbled....More>>>
Allergan (NYSE:AGN) is one of the many biotech stocks that has been beaten down in the last one and a half year. In this article I will indicate 4 reasons why I think the company and the stock can perform well in the future.
Reason #1: Diversified sources of revenue and rich pipeline
One of the characteristics that I like in Allergan is its rich portfolio of drugs. As we can see....More>>>
bluebird bio, (NASDAQ:BLUE) is one of the oncology immunotherapy stocks I mentioned recently as worth a good look, (article titled ‘Immunotherapy Over Reaction’, a basic primer to the immunotherapy subsector and its ETF). BLUE is also a recent Cramer pick. Immunotherapy stocks have been hit hard over the summer but BLUE is a relatively highly valued genetic specialist, with some interesting....More>>>
Puma Biotechnology (NASDAQ:PBYI) ended the day down 13.8% after Roche (NASDAQOTH:RHHBY) reported that its rival breast cancer drug, Perjeta, had passed its phase 3 trial, dubbed “Aphinity.”
Image source: Getty Images.
In Roche’s trial, patients either took Perjeta and Herceptin with chemotherapy or just Herceptin with chemotherapy,....More>>>
One of the smaller details of Trumpcare, the redacted version of Obamacare, is the elimination of a tax imposed on manufacturers of medical devices. While the fate of pre-existing conditions has been hogging the spotlight in recent days, this particular tax and its future could have an impact on companies like Ventripoint Diagnostics (OTCMKTS: VPTDF TSE:VPT), and other small cap biotech....More>>>
Starting with a simple tweet on September 21st, 2015, Hillary Clinton has been pummeling Biotech stocks since her Presidential Campaign first began. In fact, Clinton has caused dramatic drops in the iShares Nasdaq Biotechnology ETF (IBB) at least three times in the past 14 months. The thought of Clinton winning the presidency, and the corresponding assault on the Biotech sector,....More>>>
Its been said of biotech that its the wild west of the investment world. There may be gold in the hills but you better have a good map and a keen eye to find it. One such company that is shimmering of late is Ventripoint Diagnostics (OTC: VPTDF), the Toronto, Ontario based developer of medical devices. With its new cardiac imaging device, the VMS Plus , Ventripoint is changing the way....More>>>